Benzinga | Apr 13, 2021 07:40AM EDT

Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology Virtual Annual Meeting

- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the first week of treatment

- Post-hoc analysis of rimegepant in the acute treatment of migraine dosed on an as needed (p.r.n.) basis demonstrated clinically relevant reductions in monthly migraine days over time

- Intranasal zavegepant pivotal Phase 2/3 trial met co-primary endpoints and demonstrated rapid onset of action with pain relief as early as 15 minutes

- Spinocerebellar ataxia study suggests an attenuation of disease progression in patients treated with troriluzole in a 96-week open label extension protocol

- Additional new and encore oral presentations and posters demonstrate advancements across multiple clinical programs including Nurtec(r) ODT (rimegepant), zavegepant, verdiperstat and troriluzole